Executive Summary
SoldierPoint Digital Health, LLC won a $237.7M obligated VA delivery order for IT architecture and application development (NAICS 541512), with base + options ceiling of $862.8M through potential 2029. This underscores robust federal healthcare IT demand but carries execution risks from firm-fixed pricing and $58.9M in subawards with zero outlays to date.
Investors should monitor option exercises for revenue upside amid subcontractor dependencies.
Materiality, sentiment, and priority are scored by Gunpowder’s analysis pipeline. How we score filings →
Tracking the trend? Catch up on the prior Federal IT & Cybersecurity Contracts digest from March 29, 2026.
Investment Signals (1)
- VA $238M IT Award with $863M Ceiling (HIGH)▲
Full-and-open competed delivery order to SoldierPoint for computer systems design, signaling strong federal IT backlog growth.
Risk Flags (2)
- Execution [MEDIUM RISK]▼
Firm-fixed price over 2-5 years risks cost overruns for SoldierPoint.
- Execution [MEDIUM RISK]▼
Reliance on 19 subawards totaling $58.9M introduces performance dependencies.
Opportunities (2)
- ◆
$625M upside via option exercises from current $238M obligation.
- ◆
3-year extension potential to 2029-09-06.
Sector Themes (1)
- ◆
Massive $863M ceiling commitment to architecture/app dev signals priority on digital health infrastructure.
Watch List (1)
- 👁
{"entity"=>"SoldierPoint Digital Health, LLC", "reason"=>"$863M VA potential dwarfs $238M start; zero outlays flags revenue timing.", "trigger"=>"Initial outlays or option notice"}
Get daily alerts with 1 investment signals, 2 risk alerts, 2 opportunities and full AI analysis of all 1 filings
$30/mo after a 14-day free trial — no credit card required. See pricing or explore intelligence streams.
More from: Federal IT & Cybersecurity Contracts
🇺🇸 More from United States
View all →May 27, 2026
US Pre-Market SEC Filings Roundup — May 27, 2026
US Pre-Market SEC Filings Roundup
May 27, 2026
S&P 500 Technology Sector SEC Filings — May 27, 2026
S&P 500 Technology Sector SEC Filings
May 27, 2026
Orphan Drug Approvals — May 27, 2026
Orphan Drug Approvals
May 27, 2026
Big Pharma Approvals — May 27, 2026
Big Pharma Approvals